|
| 37414703 | Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data. | Eur Urol | 2024 |
| 36749636 | Increased use of 6-monthly gonadotropin-releasing hormone agonist therapy for prostate cancer: a capacity and cost-minimization analysis for England. | J Med Econ | 2023 |
| 38046899 | Research protocol to identify progression and death amongst patients with metastatic hormone-sensitive prostate cancer treated with available treatments: PIONEER IMI's "big data for better outcomes" program. | Int J Surg Protoc | 2023 |
| 37117107 | Impact of Epithelial Histological Types, Subtypes, and Growth Patterns on Oncological Outcomes for Patients with Nonmetastatic Prostate Cancer Treated with Curative Intent: A Systematic Review. | Eur Urol | 2023 |
| 36813168 | ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. | Radiother Oncol | 2023 |
| 34147405 | Evaluation of Oncological Outcomes and Data Quality in Studies Assessing Nerve-sparing Versus Non-Nerve-sparing Radical Prostatectomy in Nonmetastatic Prostate Cancer: A Systematic Review. | Eur Urol Focus | 2022 |
| 35857753 | Initial experience with AI Pathway Companion: Evaluation of dashboard-enhanced clinical decision making in prostate cancer screening. | PLoS One | 2022 |
| 35562268 | TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification. | Eur Urol | 2022 |
| 36291905 | A Systematic Review to Evaluate Patient-Reported Outcome Measures (PROMs) for Metastatic Prostate Cancer According to the COnsensus-Based Standard for the Selection of Health Measurement INstruments (COSMIN) Methodology. | Cancers (Basel) | 2022 |
| 35184906 | Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. | Eur Urol | 2022 |
| 34980492 | Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. | Eur Urol | 2022 |
| 34785188 | Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. | Eur Urol Oncol | 2022 |
| 33967010 | Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. | Eur Urol Focus | 2022 |
| 33039206 | EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. | Eur Urol | 2021 |
| 34598912 | Providing a Framework for Meaningful Patient Involvement in Clinical Practice Guideline Development and Implementation. | Eur Urol Focus | 2021 |
| 33965893 | Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. | Cancer Treat Rev | 2021 |
| 33962808 | A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. | Eur Urol | 2021 |
| 33172724 | EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. | Eur Urol | 2021 |
| 33423943 | A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. | Eur Urol Oncol | 2021 |
| 33129581 | IMAGINE-IMpact Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines. | Eur Urol | 2021 |
| 31248850 | Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. | Eur Urol Focus | 2020 |
| 31992464 | European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management. | Eur Urol | 2020 |
| 31829902 | Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. | J Clin Oncol | 2020 |
| 32863055 | Precision Oncology for Metastatic Prostate Cancer: Translation into Practice. | Eur Urol | 2020 |
| 32624287 | Prostate-specific Membrane Antigen Positron Emission Tomography Scans Before Curative Treatment: Ready for Prime Time? | Eur Urol | 2020 |
| 32821347 | Correction: Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. | Oncotarget | 2020 |
| 32146018 | Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. | Eur Urol | 2020 |
| 30473433 | Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. | Eur Urol | 2019 |
| 31036524 | The Success and Evolution of a Urological "Boot Camp" for Newly Appointed UK Urology Registrars: Incorporating Simulation, Nontechnical Skills and Assessment. | J Surg Educ | 2019 |
| 30342843 | Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. | Eur Urol | 2019 |
| 29103760 | Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. | Eur Urol | 2018 |
| 32700031 | Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient-Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study. | Oncol Ther | 2018 |
| 29937198 | Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018. | Eur Urol | 2018 |
| 30270127 | Harnessing New Media Tools in Patient Information. | Eur Urol | 2018 |
| 29373215 | Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. | Eur Urol | 2018 |
| 27568654 | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. | Eur Urol | 2017 |
| 28415688 | Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. | Oncotarget | 2017 |
| 28336078 | What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. | Eur Urol | 2017 |
| 28126351 | The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. | Eur Urol | 2017 |
| 28757301 | Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. | Eur Urol | 2017 |
| 27591931 | EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. | Eur Urol | 2017 |
| 26691493 | Role of Hormonal Treatment in Prostate Cancer Patients with Nonmetastatic Disease Recurrence After Local Curative Treatment: A Systematic Review. | Eur Urol | 2016 |
| 27779102 | The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. | Oncotarget | 2016 |
| 25133826 | The association of metacognitive beliefs with emotional distress after diagnosis of cancer. | Health Psychol | 2015 |
| 25657483 | A Prospective Study of the Association of Metacognitive Beliefs and Processes with Persistent Emotional Distress After Diagnosis of Cancer. | Cognit Ther Res | 2015 |
| 20060331 | Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. | Urol Oncol | 2011 |
| 17219417 | Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition. | Mol Carcinog | 2007 |
| 17949319 | Routine use of magnetic resonance imaging in the management of T(1c) carcinoma of the prostate: is it necessary? | J Endourol | 2007 |
| 16539727 | Surveillance of testicular microlithiasis? Results of an UK based national questionnaire survey. | BMC Urol | 2006 |
| 16720000 | PSA testing: are patients aware of what lies ahead? | Ann R Coll Surg Engl | 2006 |